Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Stroke Prevention With Evidence-Based DOAC Therapy

Credits Available
Pharmacists: 0.5 contact hours (0.05 CEUs)
Released: April 13, 2022 Expiration: April 12, 2023
Start Activity
Provided by ProCE, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bristol-Myers Squibb
Pfizer Alliance
Stephanie Dwyer Kaluzna, PharmD, BCCP
Kathleen A. Lusk, PharmD, BCPS, BCCP

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Apply guideline recommendations, clinical trial evidence, and patient-specific factors to select DOACs for appropriate patients diagnosed with NVAF

Information on this Educational Activity

ProCE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty

Kathleen A. Lusk, PharmD, BCPS, BCCP

Associate Professor
Vice Chair

Department of Pharmacy Practice
University of the incarnate Word Feik School of Pharmacy
Adjunct Assistant Professor
Clinical Pharmacy Specialist

Division of Cardiology
Department of Medicine
UT Health San Antonio
San Antonio, Texas

Kathleen A. Lusk, PharmD, BCPS, BCCP, has no relevant conflicts of interest to report.
Stephanie Dwyer Kaluzna, PharmD, BCCP

Clinical Assistant Professor
Department of Pharmacy Practice
University of Illinois Chicago College of Pharmacy
Cardiovascular Clinical Pharmacist
University of Illinois Hospital and Health Sciences System
Chicago, Illinois

Stephanie Dwyer Kaluzna, PharmD, BCCP, has no relevant conflicts of interest to report.

Staff

Kimberly Nealy, PharmD, BCPS, CDCES, CPP

Scientific Director

Kimberly Nealy, PharmD, BCPS, CDCES, CPP, has no relevant conflicts of interest to report.
Ruth Cohen Cooper, CHCP

Vice President, Science and Strategy

Ruth Cohen Cooper, CHCP, has no relevant conflicts of interest to report.
Petra Cravens, PhD

Editorial Contributor

Petra Cravens, PhD, has no relevant conflicts of interest to report.
Susan Daniels, PhD
Scientific Director
Susan Daniels, PhD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

The target audience is pharmacists, including clinical and health-system, ambulatory care, and community pharmacists, who care for patients with or at risk for NVAF. In addition, the target audience includes pharmacy directors, chief pharmacy officers, and other stakeholders in pharmacy practice.

Goal

The goal of this program is to improve the knowledge, competence, and performance of pharmacists regarding the implications of undiagnosed NVAF, types of detection for NVAF, the need to counsel and follow up with individuals who are at risk for or detected/diagnosed with NVAF, and the need to enhance collaboration with other HCPs to improve patient care.

Continuing Pharmacy Education

ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-22-032-H01-P has been assigned to this home study, knowledge-based activity. This activity is approved for 0.5 contact hours (0.05 CEUs) in states that recognize ACPE providers. The activity is provided at no cost to participants. Completion of an evaluation and post-test with a score of 100% or higher is required to receive CE credit. Proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from April 13, 2022, through April 12, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Stroke Prevention With Evidence-Based DOAC Therapy

Loading...
In this microlearning module, an expert faculty provides evidence-based recommendations on the use of DOAC therapy in NVAF for stroke prevention.
Stephanie Dwyer Kaluzna, PharmD, BCCP
Kathleen A. Lusk, PharmD, BCPS, BCCP
Pharmacists: 0.5 contact hours (0.05 CEUs)
Released: April 13, 2022 Expiration: April 12, 2023

Related Content

Dr. Katherine Di Palo discusses use of novel potassium binders for the management of hyperkalemia, from ProCE

Katherine Di Palo, PharmD Released: May 13, 2022

Expert faculty provide practical strategies for successful management of hyperkalemia from ProCE

Katherine Di Palo, PharmD Michelle Richardson, PharmD, BCPS Pharmacists: 1.5 contact hours (0.15 CEUs) Released: May 12, 2022 Expired: May 11, 2023

Downloadable slides featuring expert insights on engaging patients and the healthcare team in collaborative, shared decision-making from ProCE.

Stephanie Dwyer Kaluzna, PharmD, BCCP Kathleen A. Lusk, PharmD, BCPS, BCCP Released: April 13, 2022

A quick reference guide for the screening and management of NVAF, from ProCE

Stephanie Dwyer Kaluzna, PharmD, BCCP Kathleen A. Lusk, PharmD, BCPS, BCCP Released: April 13, 2022
Provided by ProCE, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bristol-Myers Squibb
Pfizer Alliance

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings